We are currently investigating intermittent issues affecting access to some articles and pages on our site. We apologize for any inconvenience and are working to resolve this as quickly as possible.

Genus shares rally with profit projected ahead of expectations

(Alliance News) - Genus PLC on Wednesday reported a strong start to financial 2025, with ...

Alliance News 15 January, 2025 | 10:21AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Genus PLC on Wednesday reported a strong start to financial 2025, with half-year profit predicted ahead of expectations.

The London market rallied behind the Basingstoke, England-based biotechnology and genetics company, as Genus shares rose 21% to 1,718.00 pence each on Wednesday morning.

Genus anticipates adjusted pretax profit for the six months to December 31 will be at least GBP35 million, up from GBP29.2 million the year prior.

This estimate is at the high-end of market expectations. It is given in actual currency and assumes a constant currency headwind of GBP8 million to GBP9 million in the 2025 financial year.

Genus said its bovine genetics branch ABS had delivered in line with expectations since the firm's last update in November. PIC, the porcine genetics arm, had traded at higher volumes than expected, and saw adjusted operating profit rise in the North American and Asian markets.

Progress continues on Genus's Resistant Pig programme, which is undergoing review by the US Food & Drug Administration and other international regulators.

Publication of the half-year results is scheduled for February 27.

By Holly Munks, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Genus PLC 1,710.00 GBX 20.08 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures